KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $61.0 million.

  • Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) fell 211.96% to $61.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year decrease of 211.96%. This contributed to the annual value of $61.8 million for FY2024, which is 229.57% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $61.0 million for Q3 2025, which was down 211.96% from $61.2 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $64.0 million during Q2 2023, with a 5-year trough of $56.5 million in Q1 2021.
  • For the 5-year period, Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $61.8 million, with its median value being $62.4 million (2022).
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 1014.97% in 2021, and later plummeted by 268.44% in 2025.
  • Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $59.7 million in 2021, then increased by 4.77% to $62.5 million in 2022, then increased by 1.2% to $63.3 million in 2023, then dropped by 2.3% to $61.8 million in 2024, then fell by 1.43% to $61.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $61.0 million for Q3 2025, versus $61.2 million for Q2 2025 and $61.8 million for Q4 2024.